The Asian Cohort for Alzheimer’s Disease (ACAD) is pleased to announce a partnership with National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD) to analyze biosamples collected through ACAD sites.
CARE, COMPASS, and ACAD Joint Statement May 16, 2022 We are disheartened by the recent mass shootings fueled by hate across our country. This public health epidemic of hate-based shootings requires interventions at all levels especially structural, and we call on all to work collaboratively to combat this serious issue.
Collaborative Approach for AAPIs Research and Education (CARE), a research recruitment registry, employs community based participatory research methods that are culturally/linguistically appropriate.
This past June, the U.S. Food and Drug Administration approved Aduhelm (aducanumab) for the treatment of Alzheimer’s disease via an Accelerated Approval pathway.
ACAD stands against anti-Asian hate. Please read through the following article for links to the ACAD statement and statements from the ACAD members’ institutions and projects.
ACAD releases a statement addressing the tragedy in Atlanta that occurred on March 16, 2021
Happy Lunar New Year! From the ACAD Study, we wish you all good health, good fortune, and a prosperous year of the Ox!
Forbes featured ACAD MPI Dr. Park in an article for her work using Korean dramas as a mental health education tool for Asian Americans.
ACAD applauds President Biden’s Executive Order condemning and combating racism, xenophobia, and intolerance against AAPIs.
The Asian Cohort for Alzheimer’s Disease (ACAD) recently received a pilot grant from the National Institute on Aging. Continue reading for more information and to find Penn Medicine’s press release highlighting the award.